Plain-English translation of NCT02521311 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a medication called can help repair the protective coating around the optic nerve after it becomes damaged and inflamed. Optic neuritis causes vision loss, blurred vision, and eye pain, and currently there are limited treatments to help the nerve heal. Researchers believe this medication might help the nerve rebuild its protective layer and restore vision.
Optic neuritis damages the protective coating around the optic nerve, leading to vision loss that may not fully recover. This medication could fill an important gap by actually helping the nerve repair itself, rather than just managing inflammation.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will be randomly assigned to receive either the medication or a placebo (inactive pill) for 3 months, then stop treatment and return for a final evaluation at 9 months. You will have regular clinic visits where your vision will be tested, your eyes will be examined, and blood tests may be done to monitor your safety. The study lasts about 9 months from start to finish.
AI-generated summary from trial data · Jul 16, 2026 · Not medical advice
United States